### FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> Abdul-Wahab Umari	2. Issuer Name and Ticker or Trading Symbol IDERA PHARMACEUTICALS, INC. [ IDRA ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify									
(Last) (First) (Middle) C/O IDERA PHARMACEUTICALS, INC.	3. Date of Earliest Transaction (Month/Day/Year) 01/02/2014	below) below)									
167 SIDNEY STREET (Street) CAMBRIDGE MA 02139	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person									
(City) (State) (Zip)											
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											

#### 2A. Deemed 5. Amount of 1. Title of Security (Instr. 3) 2. Transaction 4. Securities Acquired (A) or 6. Ownership 7. Nature Transaction Code (Instr. Date Execution Date, Disposed Of (D) (Instr. 3, 4 Securities Form: Direct of Indirect (Month/Dav/Year) Beneficially (D) or if anv and 5) Beneficial (Month/Day/Year) 8) Owned Indirect (I) Ownership Following (Instr. 4) (Instr. 4) Reported (A) 01 Code v Amount Price . Transaction(s) (D) (Instr. 3 and 4) Common Stock 01/02/2014 A 1,842(1) \$4.75 65,320 D Α

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, cans, warrants, options, convertible securities)																L	
	1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		d 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					

Explanation of Responses:

1. This stock was issued to the reporting person pursuant to the Issuer's director compensation program in lieu of cash.

**Remarks:** 

/s/ Abdul-Wahab Umari 01/06/2014

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.